SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol	
ANIDO ARMANDO (Last) (First) (Middle) C/O ZYNERBA PHARMACEUTICALS, INC. 80 W. LANCASTER AVENUE, SUITE 300 (Street) DEVON PA 19333 (City) (State) (Zip)	08/04/2015	Zynerba Pharmaceuticals, Inc. [ZYNE] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director; 10% Owner X Officer (give title below); Other (specify below) Chairman & Chief Exec. Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock(1)	332,512	D	
Series 1 Convertible Preferred Stock	50,000	I	By TUA of Armando Anido
Series 1 Convertible Preferred Stock	25,000	I	By Nancy J. Anido Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option	(2)	10/02/2024	Common Stock	292,553	3.98	D	

Explanation of Responses:

1. Shares are restricted stock. The restrictions lapse as to 25% of the restricted stock as of the date of the closing of the Issuer's initial public offering, with the remaining restrictions lapsing in twelve equal quarterly installments thereafter.

2. The stock option vests as to 25% of the common stock as of the date of the closing of the Issuer's initial public offering, with the balance vesting in twelve equal quarterly installments thereafter.

Remarks:

Armando Anido 08/04/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.